While no conclusive clinical evidence has been found to suggest that GLP-1 RAs are tumorigenic, numerous studies have indicated their potential to inhibit the growth of ovarian, breast, prostate, and pancreatic cancers [29,30,31,32,33,34,35,36]. Here, GLP1R is linked to pancreatic neoplasm.